

## SuperSonic Imagine Showcases Clinical Innovations During The European Congress of Radiology

### *SuperSonic Imagine Hosts Symposium on UltraFast™ Imaging: A New Paradigm for Ultrasound Diagnosis*

**Aix-en-Provence, France, March 1st, 2016** – SuperSonic Imagine (Euronext: SSI, FR0010526814), the highly innovative ultrasound company, announced today its participation in the European Congress of Radiology (ECR) March 2 - 6, in Vienna, Austria, to demonstrate the clinical benefits of real-time ShearWave™ Elastography (SWE™) in assessing major diseases such as chronic liver disease and cancer of the breast, prostate and thyroid as well as in the domain of musculoskeletal imaging. The Company is also featuring two new innovations during the Congress, which they will be demonstrating on the show floor (**booth #4 in Exhibit Hall A**).

SuperSonic Imagine will showcase its new solution for microvascular visualization, Angio PL.U.S. – Planewave UltraSensitive™ imaging. Angio PL.U.S. is a significant advancement in Color Doppler Imaging. Conventional Doppler is limited in its ability to show microvascular slow flow. Angio PL.U.S. provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. It increases the detail of real-time flow information available during ultrasound diagnostic exams. This information is instrumental in helping the diagnosis of cancerous tissues in areas such as the liver, lymph nodes and thyroid as well as musculoskeletal pathologies such as inflammation in tendons. Angio PL.U.S. leverages SuperSonic Imagine's previous innovation, UltraFast™ Doppler, providing an advanced solution for vascular evaluation.

Also during ECR, SuperSonic Imagine will be highlighting the clinical benefits a new SuperEndocavity™ Volumetric transducer, the unique endo transducer on the market that enables 2D AND 3D imaging for B-Mode, Color modes and SWE. This information is very useful in the diagnosis and monitoring of prostate cancer as well as for gynecologic and obstetrics applications.

Both of these latest innovations can be found as part of SuperSonic Imagine's platform Aixplorer®, the only ultrasound system available that provides SWE in real-time. SWE is a quick, non-invasive exam that provides color coded maps and quantitative measurement of tissue stiffness. This information is used by physicians to help identify potentially malignant or other diseased tissue. As of today, over 300 peer-reviewed articles have demonstrated the clinical benefits of SWE in a wide range of clinical applications.

"Clinicians are eager for imaging advances and new tools to help identify and diagnose suspicious lesions while avoiding unnecessary imaging or biopsies," said Jacques Souquet, SuperSonic Imagine's Chief Innovation Officer and Founder. "Angio PL.U.S. and our new 3D endo transducer combined with our existing innovations, SWE and UltraFast™ Doppler, represent significant advancements to the arsenal of non-invasive diagnostic tools for cancer or other major diseases."

"From my experience, the new 3D endocavity transducer brings significant improvement to prostate imaging with ultrasound and could provide a true alternative to multi-parametric MRI imaging currently used for prostate cancer" said Pr. Jean-Michel Correas, Vice Chairman of the Adult

Radiology Department at Necker University Hospital, Paris, France. “With 3D ShearWave Elastography, for the first time, we are able to clearly identify and target suspicious regions of the prostate with an ultrasound based technique.”

During the ECR (March 2, 12:30 – 1:30pm, Room N), SSI will host a symposium “UltraFast Imaging: A New Paradigm for Ultrasound Diagnosis – How innovations derived from UltraFast Imaging are improving diagnosis and patient management across diseases”. Participants will include Dr. Maja Thiele, Prof. FKW. Schafer, Prof. JM. Correas, and Mr. Mickael Tanter. For additional information or to register can be found [here](#).

Additional information about ECR can be found [here](#). The Company will be exhibiting at **booth #4 in Exhibit Hall A** and will be hosting live demonstrations at the booth throughout the meeting.

### **About SuperSonic Imagine**

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to [www.supersonicimagine.com](http://www.supersonicimagine.com).

### **Contact information:**

#### **SuperSonic Imagine**

Corporate  
Bernard Doorenbos  
[bernard.doorenbos@supersonicimagine.com](mailto:bernard.doorenbos@supersonicimagine.com)  
+33 6 15 66 64 68

#### **NewCap**

Investor Relations – EU  
Pierre Laurent / Florent Alba  
[supersonicimagine@newcap.fr](mailto:supersonicimagine@newcap.fr)  
+33 1 44 71 98 55

#### **SuperSonic Imagine**

Marketing & Communication  
Emmanuelle Vella  
[emmanuelle.vella@supersonicimagine.com](mailto:emmanuelle.vella@supersonicimagine.com)  
+33 4 86 79 03 27

#### **Pascale Communication**

Media Relations - US  
Amy Phillips  
[amy@pascalecommunications.com](mailto:amy@pascalecommunications.com)  
+1 412 327 9499

#### **Blueprint Life Science Group**

Investor Relations - US  
Candice Knoll [cknoll@bplifescience.com](mailto:cknoll@bplifescience.com)  
+1 415 375 3340 Ext. 4